FDA Delays Action On Amgen’s Nplate
This article was originally published in The Pink Sheet Daily
Executive Summary
Little effect on bottom line, analyst tells “The Pink Sheet” DAILY.
You may also be interested in...
For Amgen’s Nplate, No News Is Good News
FDA tells biotech the agency will miss once-postponed July 23 user fee date.
For Amgen’s Nplate, No News Is Good News
FDA tells biotech the agency will miss once-postponed July 23 user fee date.
Nplate Risk Plan Includes Patient Support Initiatives
Prematurely issued press release announcing approval of Amgen chronic ITP therapy provides details on risk evaluation and mitigation strategies.